Cytori Therapeutics (CYTX)

Business description

Cytori is focused on the development of cellular therapeutics for the treatment of impaired hand function in scleroderma, osteoarthritis of the knee, and radiation exposure-associated deep thermal burns.

Share price chart

Share chart

Stock data

Market cap.US$58m
Last closeUS$0.37
High / Low (52 weeks)US$1.4 / US$0.3
Stock market listingUS
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
SectorPharmaceutical & Healthcare

Price performance

Relative *1.317.1(16.5)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
Agennix Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
Astex Pharmaceuticals Athersys
Atossa Genetics Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Celyad
Cerulean Pharma Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
co.don AG Consort Medical
Curis Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics EKF Diagnostics
Emergent BioSolutions Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Forward Pharma
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab Genticel
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
ImmuPharma Imprimis Pharmaceuticals
Imugene Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Lifewatch AG Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
Molecular Partners MolMed
Mologen AG Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
NeoStem Neovacs
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Ossur OvaScience
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Quantum Pharmaceuticals Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
RXi Pharmaceuticals Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals TearLab Corp
Tekmira TESARO
Theraclion Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Group Tissue Therapies
Tonix Pharmaceuticals Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals TruScreen Ltd
UDG Healthcare uniQure NV
Universal Biosensors Vectura
Verastem Verisante Technology
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
VolitionRx WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

Company Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) Rally 12.86%

Mon, 30 Nov 2015 01:18:45 GMT

Cytori Therapeutics Inc Short Interest Update

Wed, 25 Nov 2015 12:33:45 GMT

Cytori Therapeutics Inc (NASDAQ:CYTX) Sentiment Report

Mon, 23 Nov 2015 15:01:16 GMT

Stock Update (NASDAQ:CYTX): Phase I Trial of Cytori Therapeutics Inc Cell ...

Thu, 22 Oct 2015 13:18:45 GMT

Cytori Therapeutics Inc's Trend Down, Especially After Forming a Bearish ...

Wed, 25 Nov 2015 21:11:15 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2013A 12.2 (32.6) (38.1) (56.2) N/A N/A
2014A 10.1 (34.7) (41.2) (52.5) N/A N/A
2015E N/A N/A N/A N/A N/A N/A
2016E N/A N/A N/A N/A N/A N/A

Last updated on 18/11/2015

Investment summary

Cytori's pivotal Phase III STAR trial, started in August 2015, will assess its cell therapy (ECCS-50) in up to 80 patients with impaired hand function from scleroderma. This follows a Phase I/II pilot trial whereby treatment showed significant improvements at 12 months across several measures. A follow-up co-sponsored pivotal study (SCLERADEC-II) in France started this month. Recruitment for a 94-patient US Phase II study in knee osteoarthritis was recently completed; data are due in Q116. 9M15 product revenue was $3.3m with an operating cash burn rate of $15.9m. Q315 net cash was $2.5m ($19.0m gross cash, c $16.4m debt). Cytori's cash resources should last into Q316. Cytori is not currently under our full coverage.

Last updated on 25/11/2015

Industry outlook

The $14m BARDA thermal burns therapy contract is progressing. A 45-pt Japanese government funded urinary incontinence study (ADRESU) started in September 2015. Kerastem, Celution licensee for alopecia, received clearance to start a 70-pt US study, planned to start in Q415.

Last updated on 25/11/2015

Key management

Marc Hendrick, CEO
Tiago Girao, CFO

Company address

3020 Callan Road
San Diago
CA 92121
United States
View website